Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

With the transaction exceeding 300 million US dollars reached, how is the exploration of Chinese inhibitor KRAS G12C?

PharmaSources/YefenghongSeptember 14, 2021

Tag: KRAS G12C , pharma transaction , lung cancer , Amgen AMG510

PharmaSources Customer Service